Ovarian Cancer

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

Go to full article published by the FDA.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

In precision oncology, drugs combinations may provide new effective treatment.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

Go to full article published by CAP Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:

Treatment with pembrolizumab (brand name Keytruda) on its own shows modest responses in patients with recurrent ovarian cancer.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

Go to full paper published in the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from The New England Journal of Medicine curated by Editor in Chief George Lundberg, MD, who notes: 

These clinical trials results suggest that the drug niraparib is superior to platinum-based chemotherapy for people with newly diagnosed advanced ovarian cancer.

Go to full paper published in The New England Journal of Medicine.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.

Go to full paper published in the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt:

“ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.”

Go to full article published by The ASCO Post on Aug 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt:

“At first glance, a bill passed by the House of Representatives this week seems like the kind of thing anyone could get behind.

“Known as the “Right to Try” legislation, it would allow terminally ill patients access to experimental drugs without the approval of the Food and Drug Administration.

“But the bill and a similar one passed last summer by the Senate do little to address the main barrier that patients face in getting unapproved treatments: permission from the drug companies themselves.”

Go to full article published by The New York Times on Mar 23, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Philadelphia Inquirer curated by Editor in Chief George Lundberg, MD, who notes: 

A new Pennsylvania law requires insurance coverage for use of FDA-approved best drugs first, rather than only after failing with a cheaper alternative.

Go to full article published by The Philadelphia Inquirer.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

Go to full paper published in Nature.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from the American Society of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

For now, the only definite preventive measures vulnerable patients with cancer can use for themselves and their families are scrupulous social distancing and enhanced personal hygiene; i.e., wash your hands. For more details, ASCO is an authoritative source:

Go to full article published by the American Society of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.